

**Minutes of Public Meeting  
DHCFP Drug Utilization Review Board  
September 18, 2003**

**Attending:**

**Carson City:**

Charles Duarte  
Jeff Monaghan  
Coleen Lawrence  
Dionne Coston  
Francis Pope  
Ritz Owen  
Mary Wherry  
Anita Sheard

**Las Vegas:**

Patty Miller  
Wyeth Pharm. Rep.  
Wyeth Pharm. Rep

**Telephone Conference:**

Dave England, Pharm D. Chairman  
Joseph W. Johnson, MD, Member  
Steven Parker, MD, Member  
Lori Winchell, RNP, Member  
Nancy Davis, RN, First Health

Pharmaceutical representatives included: Paul Pereira, TAP; Tracy Davies, Eli Lilly Co; Ellen McCormick, Astra Zeneca; Rosy Suleman and Angela McCoy, Janssen; David Shestak, Johnson & Johnson; Jean Cronin and Carla Clooney, Astra Zeneca; Keith Hollingsworth, Takeda; Kara Smith, Boehringer Ingelheim; Jim Goddard, Shire Pharmaceuticals

**Agenda Item I.**

Coleen Lawrence, Chief of Program Services of DHCFP, opened the public meeting with an acknowledgement of the work the Drug Utilization Review Board has accomplished throughout the 2003 legislative session. A large amount of data was analyzed by the board members for legislation under consideration, with 3 major pieces of legislation adopted. DHCFP, in addition to the implementation of Point of Sale (POS) on February 1, 2003, is still on target to go live with the new Medicaid Management Information System (MMIS) on October 1, 2003. The electronic formats and more rapid claims processing are an anticipated benefit to all providers.

Ms. Lawrence introduced Jeff Monaghan of First Health (FH), who is the Pharmacy Program Clinical Manager and will be working with the DUR Board.

Mr. Monaghan expressed appreciation for the opportunity to work with the DUR Board and the Nevada Medicaid staff and assured members that First Health has a depth of resources available to assist the division with pharmacy utilization issues.

**Agenda Item II.**

Chairman Dave England officially called the meeting to order at 1:10pm with a quorum participating by telephone conferencing. The meeting was facilitated in Carson City at the Legislative Building Room 3137 by Ms. Lawrence and in Las Vegas from the Grant Sawyer Building by Patty Miller, Medicaid District Office Manager. Those in attendance are listed on the attached sheets.

**Agenda Item III.**

Dr. Steven Parker moved acceptance of the minutes of the June 19, 2003 meeting as written. Lori Winchell seconded and the motion was adopted.

**Agenda Item IV. Administrator's Report**

Charles Duarte presented highlights of the 2003 Legislative Session and the Medicaid Budget. Pharmaceutical therapy issues were a significant part of the session, with the main focus being to reduce pharmaceutical costs by and for Medicaid recipients through the establishment of a Preferred Drug List (PDL). The DUR Board members will be assisted by members the new Pharmaceutical & Therapeutic Advisory Committee, so that the workload will not become burdensome on the DUR Board. There are a number of issues to implement with the help of FH Services.

- AB384 indicates the importance of the DUR Board in implementing pharmacy policy
- An Advisory Committee of the P&T will have representatives of the AARP, NAMI and the developmentally disabled support community. The appointments will be made by the Director of the Department of Human Resources. Orientation will be provided by Medicaid staff with the input and assistance of the DUR Board.

- The DUR Board members can assist the department in reviewing all drugs and especially in the TMAP processes.

The Division is working to determine that policies are aligned properly with sister agencies within the Department in the mental health field. An algorithm can be adopted for the therapeutic classes to ensure all the therapy drug classifications are considered when adopting an algorithm for Nevada Medicaid.

Mr. England stated it was his understanding the DUR Board will continue to function as it is and asked what the function and participation of FH will be.

Mr. Monaghan responded FH is one of several bidders for the Preferred Drug List (PDL) and the Maximum Allowable Cost (MAC) areas. Nevada will be the 7<sup>th</sup> or 8<sup>th</sup> state FH has assisted in the development of a PDL and establishment of a MAC. It will be the responsibility of the Pharmaceutical and Therapeutic (P&T) Committee to decide what is best for Nevada citizens. The DUR Bd. will work closely with the P&T Committee to assist FH. FH will perform the functions formerly provided by Health Information Designs (HID) for DHCFP and the DUR Board.

Mr. Duarte indicated regulation issues will go forth after 10/01/2003, however prior to the first meeting guidelines and bylaws will have to be developed. Target date for the first P&T Committee meeting is January 2004. In the process, we hope to bring new members to the DUR Board as well as the P&T Committee and the Advisory Board.

Mr. England asked if there were any comments from those attending.

Carson City: Keith Hollingsworth, Takeda Pharmaceuticals, inquired whether the PDL would be based on the Oregon model.

Mr. Duarte indicated the Oregon model representative, Mark Gibson, could not commit to the time schedule needed.

Mr. Hollingsworth stated the Oregon information included 12 classes of PDL information.

Mr. England assured Mr. Hollingsworth the DUR Board would be using reliable and quantifiable sources to obtain the best information available.

#### Agenda Item VI. Prospective Drug Utilization (ProDUR)

Mr. Monaghan discussed the summary report information on ProDUR as received by the Board members in their packets. The members discussed and questioned items shown.

Nancy Davis, Clinical Pharmacy Manager for First Health in Virginia, pointed out the data is reviewed for a payment rate in the 70% range. The report under discussion shows 70% pay rate which is good, and which is up from the 50% where it started in March, 2003 after the Point of Sale (POS) implementation. Payment rates usually rise and stabilize in the 70 percentile area.

Dr. J. W. Johnson joined the meeting by teleconference at this point, 1:35pm. The discussion on the ProDUR report continued.

Mr. England asked whether the Board would consider a vote on additional edit denials or prefer to have additional information.

Dr. Johnson moved the consideration of additional edit denials be tabled until the next regular meeting when additional information is received from First Health. Lori Winchell seconded the motion and it was adopted.

Mr. England asked if there were any comments.

Carson City: David Shestak, Johnson & Johnson Pharmaceuticals, asked if the material being reviewed was available to the pharmacy company representatives attending the meeting. A response or comment is not possible if there is no access to the material.

Mr. Duarte responded the information being reviewed by the Board contains patient and provider specific data which cannot be made available under HIPAA privacy guidelines. The Division's Deputy Attorney General will review the reports to determine a format so that in the future information can be available for public review prior to the meeting.

Agenda Item VII. Retrospective Drug Utilization Review (RetroDUR)  
Mr. England asked for discussion on the RetroDUR process.

Mr. Monaghan pointed out items in the report for consideration by the Board. The report contained actual profiles as reviewed by clinical pharmacists and prescribers.

Mr. Duarte indicated again that future reports will be redacted so that copies without patient and provider specific information are available.

Mr. England stated this is a large quantity of criteria to review and requested the information be provided so that the Board could review a class of drug at a time.

Mr. Duarte indicated that because the reports are not available to the general public at this time, he would recommend action be tabled to a further time, so that public review and comment time could be scheduled prior to the meeting.

Ms. Lawrence said the Board was free to take action on the Duragesic Criteria Review at this time because it was discussed at an earlier meeting of the Board.

Dr. Johnson moved to table the item until the next regular meeting. Dr. Parker seconded and the motion was adopted.

Agenda Item V. Drug Use Criteria Review

Mr. England asked whether the items should be considered or tabled for the next meeting.

Carson City: Mike Barket, Wyeth Pharmaceuticals, spoke asking that the Flumist be considered earlier than the December 2003 meeting, because the flu inoculation season is prior to that date.

Darrell Faircloth, Deputy Attorney General, advised the options available to the Board would be to schedule a special meeting to consider Flumist and Xolair prior to the December 2003 meeting or table for consideration at that time.

Ms. Lawrence indicated a special meeting can be scheduled in October.

Mr. Barket urged a meeting as soon as possible would benefit providers for the at risk population.

Agenda Item VIII. Old Business, Duragesic Criteria Review

Mr. England inquired if there is additional information on the item, as it had been covered at an earlier meeting.

Mr. Monaghan replied it is listed again because the Board had requested additional usage data to review on whether to exclude cancer patients in this area.

Mr. Shestak of Johnson & Johnson, asked whether a letter from Dr. McKenna was forwarded to Board members.

Ms. Lawrence said she did not believe the letter was received in time to be forwarded.

Mr. England asked if they would like to reschedule the presentation to the next meeting to give the members time to review the material to be presented and referenced.

Dr. Johnson stated the Duragesic information provided indicated the usage reached a plateau for 2 months.

Ms. Davis reiterated that First Health has not denied any cancer patients access to medication, however they do recommend that patients start with a liquid and progress to patches.

Mr. England questioned whether there are evidence-based studies to be considered by the Board.

Mr. Shestak introduced Rose Sulemin of Janssen Pharmaceuticals to do a brief presentation on the Clinical Value of Analgesics. Mr. Shestak then asked the Board to review the information again and indicated the

last page of the information forwarded for Board members review was confidential information and not for public distribution.

Ms. Lawrence responded to Mr. Shestak related to information sent for DUR Board review. When it contains information that is confidential, it must be so stated and DHCFP must be given permission to distribute.

Mr. England assured Mr. Shestak that pain management is an issue of real concern for the DUR Board.

Mr. Faircloth cautioned Mr. Shestak to indicate on information sent in the future what is confidential data.

Mr. Shestak said he would send out a new packet of information.

Ellen McCormick, Astra Zeneca Pharmaceuticals, asked how one could disburse information to the members of the board. She also inquired about the last page of the agenda which indicates interested parties may have action items mailed and how that is accomplished.

Francis Pope, DHCFP, responded all agendas and action items are posted on the website at least 3 days prior to each meeting. The website is <http://dhcftp.state.nv.us> in the area where public meetings are listed.

Ms. Lawrence again stated there is some information the Board reviews which is confidential under the HIPAA regulations.

Mr. England indicated that the items of Drug Use Criteria Review will be rescheduled for a called meeting before the end of October.

Dr. Parker asked that the members be sent the information to review more than 3 days in advance of the meetings.

Mr. Barket spoke again asking for review of the Flumist criteria prior to the end of October.

Mr. England thanked those in attendance.

Ms. Winchell moved adjournment of the meeting. Dr. Parker seconded and the meeting was adjourned at 2:35pm.

*This meeting was recorded. A written request is required to review the recorded transcript or a duplicated recording can be requested for a nominal fee.*